Venture CapitalKurma Partners closes Biofund IV at €215M, giving European biotech a fresh specialist pool of capitalKurma Partners has closed Biofund IV at €215 million, giving European biotech founders a meaningful new source of capital even though the vehicle came in below the €250 million target Kurma set when … more ➔
Unsplash+Ovarian cancerEpitopea wins UK approval for therapeutic vaccine trialCryptiVax-1001 is set to enter first-in-human testing in advanced high-grade serous ovarian cancer, a setting with few durable treatment options. more ➔
Svitlana Hulko-freepik.comDeep DiveCan biotech finally fix infertility?According to the WHO, one adult in six globally is affected by infertility, but beyond this statistic, infertility is best understood as a couple’s problem, even when the underlying biology … more ➔
RochePhase IIIRoche’s fenebrutinib cuts relapses in MS amid safety concernsSwiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture. more ➔
UCBAcquisitionUCB spends US$1.15bn on cell therapy biotech for potential regenerative epilepsy therapyBelgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people … more ➔
Proteins.1Protein diagnosticsProteins.1 launches with €4.7m to make protein detection as easy as PCRA newly launched Finnish deep-tech company has cracked the code for single-molecule protein detection. VTT-originated Proteins.1 has launched with €4.7m in pre-seed funding, aiming to stop the deadliest … more ➔
Boston pic by Lance Anderson via Unsplash, Collage by KnowbioVenture CapitalSpain plants US$200m flag in Boston with debut US biotech fundSpain has launched a US$200m venture capital fund anchored in Boston to help Spanish biotech companies scale in one of the world’s foremost life sciences ecosystem. The initiative includes a new trade … more ➔
Unsplash+Artificial IntelligenceNovo Nordisk is going all in on AINovo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is … more ➔
Sofinnova PartnersCapitalCan Europe finance and keep its biotech winners?The recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life … more ➔
www.istockphoto.com/YuriVenture StudiosEurope’s distinct biotech venture studio modelFor decades, biotech companies were formed around a discovery: a promising biological signal, a novel target, a platform emerging from academic research. Now a different formation model is gaining momentum: … more ➔
Unsplash+
Svitlana Hulko-freepik.com
Roche
UCB
Proteins.1
Boston pic by Lance Anderson via Unsplash, Collage by Knowbio
Unsplash+
Sofinnova Partners
www.istockphoto.com/Yuri